Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
McKinsey
Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR LEVEMIR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Levemir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00264901 ↗ Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes Completed Novo Nordisk A/S Phase 4 2005-10-01 This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to the local standard of care.
NCT00331604 ↗ Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes Terminated Novo Nordisk A/S Phase 3 2006-08-31 This trial is conducted in Asia, Europe and South America. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function tests, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combination with insulin detemir in Type 2 Diabetes.
NCT00405418 ↗ Lantus Versus Levemir Treat-To-Target Completed Sanofi Phase 4 2006-11-01 Primary objective: To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do not experience symptomatic hypoglycemia, confirmed by plasma glucose (PG) ≤ 56 mg/dL (3.1 mmol/L) Secondary objectives: - To compare between the 2 treatment groups, the percentage of patients who reach the target of HbA1c < 7% and < 6.5% at the end of the treatment period - To compare the changes in HbA1c and fasting plasma glucose (FPG) - To compare the evolution of blood glucose profiles - To compare the day to day FPG variability, the insulin doses - To determine in each treatment group the biochemical and patient-related determinants of failure to reach HbA1c targets - To compare the overall incidence and rate of symptomatic hypoglycemia and nocturnal symptomatic hypoglycemia confirmed by PG ≤ 56 mg/dL (3.1 mmol/L) - To compare over the treatment period, the overall incidence and rate of symptomatic hypoglycemia and symptomatic nocturnal hypoglycemia (with PG ≤ 70 mg/dL [3.9 mmol/L]), of symptomatic day-time hypoglycemia (with PG ≤ 70 mg/dL and with PG ≤ 56 mg/dL), of severe hypoglycemia, of asymptomatic hypoglycemia with PG ≤ 56 mg/dL - To compare the overall safety: incidence of adverse events (including serious hypoglycemia and local tolerance at injection site), change in body weight, in waist circumference and in waist / hip ratio - To assess the quality of life and treatment satisfaction
NCT00467246 ↗ Sub-Cutaneous Insulin in Hyperglycaemic Emergencies Withdrawn The Royal Bournemouth Hospital N/A 1969-12-31 Hyperglycaemic emergencies are associated with significant mortality (mortality in Diabetic Ketoacidosis 0.65 - 3.3% and in HyperOsmolar Non-Ketotic Coma 12 -17%). To reduce morbidity and mortality, prompt intervention and coma and close monitoring are essential. The study is designed to investigate whether a simple intervention with a long acting insulin can improve resolution of acidosis and hyperglycaemia, prevent recurrence of ketoacidosis and shorten hospital stay.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Levemir

Condition Name

Condition Name for Levemir
Intervention Trials
Diabetes 53
Diabetes Mellitus, Type 2 51
Diabetes Mellitus, Type 1 26
Type 2 Diabetes 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Levemir
Intervention Trials
Diabetes Mellitus 78
Diabetes Mellitus, Type 2 65
Diabetes Mellitus, Type 1 32
Hyperglycemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Levemir

Trials by Country

Trials by Country for Levemir
Location Trials
United States 144
United Kingdom 16
Germany 10
France 10
Spain 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Levemir
Location Trials
Texas 7
New York 7
Ohio 5
North Carolina 5
Washington 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Levemir

Clinical Trial Phase

Clinical Trial Phase for Levemir
Clinical Trial Phase Trials
Phase 4 29
Phase 3 4
Phase 2/Phase 3 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Levemir
Clinical Trial Phase Trials
Completed 82
Terminated 4
Unknown status 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Levemir

Sponsor Name

Sponsor Name for Levemir
Sponsor Trials
Novo Nordisk A/S 66
Sanofi 4
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Levemir
Sponsor Trials
Industry 74
Other 66
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.